Tandem Diabetes Care projects 2026 sales of $1.065‑$1.085 billion and announces CEO transition
Tandem Diabetes Care forecast total sales for 2026 between $1.065 billion and $1.085 billion. The company also disclosed that CEO John Sheridan will retire by the end of 2026 and will be succeeded by Jeannette Bankes. The outlook includes an adjusted EBITDA margin of 5%‑6% and a gross margin of 56%‑57%. The guidance and leadership change were announced together.
Why it matters
The sales guidance sets investor expectations for revenue growth in 2026, while the announced CEO succession may influence the company’s strategic direction and stock perception. The margin targets provide a view of expected profitability under the new leadership.
Key facts
- 1Tandem projects 2026 sales between $1.065 billion and $1.085 billion. seekingalpha.com
- 2CEO John Sheridan will retire by year‑end 2026. seekingalpha.com
- 3Jeannette Bankes will assume the CEO role after Sheridan’s retirement. seekingalpha.com
- 4Adjusted EBITDA margin is expected to be 5%‑6% for 2026. tokenpost.com
- 5Gross margin is expected to be 56%‑57% for 2026. tokenpost.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.